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Which policy for New Psychoactive Drugs? A Commentary  
 
Ambros Uchtenhagen 
  
 
Summary statement 
 
Psychoactive drugs have their specific profiles of potential harms and 
benefits. The increase of new drugs creates the need for procedures 
how to assess the profiles and to regulate availability and use according 
to profiles. 
 
 
 
The paper by Reuter and Pardo (1) discusses the many aspects of how 
to deal with the rapidly increasing number of what is termed “new 
psychoactive substances” (NPS). This commentary focusses on one of 
the essential aspects: the harms to individuals and society.  
 
The authors comment a total ban of NPS without considering the harms 
of a given substance as "normatively troubling". This invites to look in 
more detail at which harms are of relevance and how to assess those. 
British and Dutch experts developed models for risk and harm 
assessment (2, 3). A detailed analysis of drug harms is based on 16 
criteria in 3 clusters (physical, psychological, social) of harm to users and 
harms to others. The result of this expert consultation process is a table 
of 20 legal and illegal drugs ranked according to harms, showing 
enormous differences (4).  Another approach is to include user opinions 
besides experts to determine harms, resulting in a surprising coincidence 
between the two (5). And a recent model uses the margin of exposure 
approach MOE (ratio between medium lethal dose in animal experiments 
and estimated human intake) for determining the mortality risks of 
substances (6).   
 
All these efforts document large differences of risks and harms 
attributable to known substances, and it is reasonable to presume that 
new substances will show similar differences. However, when they are     
new on the market, we do not have the data yet which allow an 
assessment. One strategy is to estimate the risks of a new substance on 
the basis of its chemical structure, while  setting up a monitoring system 
for new drugs and collect the necessary data in a limited period of time, 
e.g. during 12 months (7). An ongoing monitoring system (collecting data 
from surveys, emergency rooms, treatment organizations, user 
organizations, toxicology e. a.) has the potential to adapt the harm 
profiles in the light of changing experiences and for informing consumer 
preferences and public health messages besides regulation strategies. A 
total ban is not only normatively troubling but also missing a chance for 
evidence-based guidance. 
 
What are the alternatives to prohibition of substances with a given harm 
profile? A number of EU Member States regulate the availability of new 
drugs under enforced consumer protection or medicines legislation, 
presenting a more flexible control system (8). So-called harm reduction 
measures are prominent in the case of legal substances, such as density 
and opening hours of alcohol outlets or smoke-free environments (9, 10). 
Such measures are in place to protect users and to prevent harm to 
others as well. Under a regime of tolerance for illegal substances, 
consumer safety is protected by qualitative and quantitative restrictions, 
e.g. for cannabis (coffee shop regulations, cannabis social clubs 
regulations). In states where cannabis prohibition is replaced by  
regulations in a licensing system, such restrictions (e.g. minimal age, 
marihuana quantities per month, number of cannabis plants, THC 
content, driving restrictions, product quality) are introduced and 
controlled (11, 12). An interim-licensing of NPS in New Zealand was 
repealed on the basis of reports of adverse effects. Pre-licensing 
assessment of substances was inadequate, and as a consequence the 
Ministry of Health prepared more appropriate requirements for product 
testing and further retail controls (13, 14). The  urgent need for tackling 
the regulatory challenges is well recognized since years (15). 
 
 
Another relevant issue is the balance of harm potential and potential 
benefits of a given substance. When discussing the option to use 
medicinal law, the Reuter/Pardo paper mentions a ruling of the European 
Court of Justice with its radical distinction of "intoxication" and "beneficial 
effects". which is problematic in the light of human experience. 
Controlled substances played a role as medicines in the past, from 
opiates to cocaine to cannabis. The dose makes the poison 
(Paracelsus). The rediscovery of beneficial effects of prohibited 
substances, starting with the prescription of Cannabis for defined 
indications, goes on for LSD (16) and Psylocibin (17). Others may follow. 
Are there more beneficial effects to be considered under medicinal law? 
Special cosmetics and nutritional products claim to improve our 
wellbeing and are sold in pharmacies. There may come a need to 
identify the relevant health benefits of NPS and the appropriate 
assessment procedures. 
  
   
 
 
 
 
References 
 
(1) Reuter P, Pardo B (2016). Can New Psychoactive Substances 
be Effectively Regulated? An Assessment of the British 
Psychoactive Substances Bill. Addiction (forthcoming) 
(2) Nutt D1, King LA, Saulsbury W, Blakemore C. (2007). 
Development of a rational scale to assess the harm of drugs of 
potential misuse. Lancet 369:1047-53 
(3) van Amsterdam J., Opperhuizen A., Koeter M. & van den Brink 
W. Ranking the harm of alcohol, tobacco and illicit drugs for the 
individual and the population. Eu. Addict Res 16:202–207  
(4) Morgan CJ1, Muetzelfeldt L, Muetzelfeldt M, Nutt DJ, Curran HV 
(2010). Harms associated with psychoactive substances: 
findings of the UK National Drug Survey. J Psychopharmacol. 
24(2):147-53 
(5) Nutt D, King LA, Phillips LD (2010). Drug harms in the UK: a   
multicriteria decision analysis. Lancet 376:1558-1565 
(6) Lachenmeier DR, Rehm J (2015). Comparative risk assessment 
of alcohol, tobacco, cannabis and other illicit drugs using the 
margin of exposure approach. Sci Rep 5:8126  
doi:  10.1038/srep08126  (accessed 20.04.2016) 
(7) McNabb CB1, Russell BR, Caprioli D, Nutt DJ, Gibbons S, 
Dalley JW (2012). Single chemical entity legal highs: assessing 
the risk for long term harm. Curr Drug Abuse Rev. 5(4):304-19 
(8) Hughes B, Winstock AS (2012). Controlling new drugs under 
market regulations. Addiction 107:1894-1 
(9) EC (2009). Report on the implementation of the Council 
Recommendation of 30 November 2009 on Smoke-Free 
Environments (2009/C 296/02) 
http://ec.europa.eu/health/tobacco/docs/smoke-
free_implementation_report_en.pdf 
(10) Popova S, Giesbrecht N, Bekmuradoc D, Patra J (2009). 
Hours and Days of Sale and Density of Alcohol Outlets: Impacts 
on Alcohol Consumption and Damage: A Systematic Review. 
Alcohol Alcoholism DOI: http://dx.doi.org/10.1093/alcalc/agp054 
500-516 
(11) Room R (2014). Legalising a market for cannabis for 
pleasure: Colorado, Washington, Uruguay and beyond. 
Addiction 109:345-351 
(12) Apfel F (2015). Cannabis – from Prohibition to Regulation. 
Alice Rap Policy Paper 5. 
(13) Wilkins C (2014). Recent developments with the 
establishment of a regulated legal market for new psychoactive 
substances (‘legal highs’) in New Zealand. Drug Alc Review 
33:678-680 
(14) EMCDDA (2015). Legal approaches to controlling new 
psychoactive substances. European Monitoring Center on 
Drugs and Drug Addiction, Lisbon   
(15) Griffith P, Evans-Brown M,  Sedefov R (2013).   Getting up to 
speed with the public health and regulatory challenges posed by 
new psychoactive substances in the information age. Addiction 
108:1700-1703          
(16)  Gasser P, Holstein D,  Michel Y, Doblin R,Yazar-Klosinski B,  
Passie T, and Brenneisen R (2014). Safety and Efficacy of 
Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety 
Associated With Life-threatening Diseases. J Nerv Ment Dis 
202:13-520 
(17) Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ,  
Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, 
Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ (2016). 
Psilocybin with psychological support for treatment-resistant 
depression: an open-label feasibility study. Lancet Psychiatry 
(http://dx.doi.org/10.1016/ S2215-0366(16)30065- 
   
 
  
 
 
 
